US FDA Proposes New Medtech Fee Categories
This article was originally published in SRA
The US Food and Drug Administration is proposing to create new user fees to pay for de novo classification reviews and pre-submission consultations, among other reforms, as part of the next user fee program (MDUFA IV)1.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.